小注塑机--大业绩

加工厂家中小型注塑机越来越普遍，其给生产和单位成本所赋予的优势并非总是那么明显清晰，本文中加工厂家对使用小型机的经验作了报告。     

Micro assembly injection moulding with plasma treated inserts

Injection moulding is one of the most common manufacturing processes for thermoplastics. By injection moulding, polymer micro components can be produced in large numbers at low costs. Micro assembly injection moulding as a combination of multi-component injection moulding and micro injection moulding enables to avoid offline process steps, as joining is already accomplished in the mould by overmoulding. In case of joint hybrid micro structures, the bonding strength between two components affects the stability of the micro system and is thus important for the part quality. Investigations carried out at the Institute of Plastics Processing (IKV), Aachen, Germany, deal with methods to increase the bonding strength of a plastic and a non-plastic part joint. As shown in the following, a plasma treatment of the inserts is an appropriate approach for this aim.     

Advances in micro assembly injection moulding for use in medical systems

In micro systems technology, the process of micro assembly injection moulding is used for the generation of hybrid micro systems. With this process, more functions are integrated in less space. In the field of medical technology, miniaturisation also means new methods of treatment with fewer side effects on the patient. New cures are developed by the miniaturisation of medical instruments, such as keyhole surgery. For detailed investigations a specific demonstration was developed to display the potential of micro assembly injection moulding in medical science. This part consists of a carbon-fibre reinforced PEEK puncture needle, which incorporates three lumens. The selected materials allow use of the needle during magnetic resonance imaging. In order to attach additional equipment a plastic connector needs to be overmoulded on the needle. The investigations focus on the injection moulding process by characterising the influences of temperature, moulding parameters and material combinations on the resulting bond strength between needle and connector.     

An experimental investigation on the influence of phenol on the solubility of CO2 in aqueous solutions of NaOH

Experimental results are presented for the solubility of CO₂ in an aqueous solution of phenol and NaOH (molalties in water: phenol: 0.5; NaOH: 1.0) at (314, 354, and 395) K and pressures up to 10 MPa. The experimental work extends recent investigations on the influence of phenol as well as of (phenol + NaCl) on the solubility of CO₂ in water. In contrast to those previous investigations, the strong electrolyte reacts with carbon dioxide and also with phenol. The experimental results are compared with predictions from a thermodynamic model. That model combines a model for the “chemical” solubility of CO₂ in aqueous solutions of NaOH with a model for the “physical” solubility of CO₂ in aqueous solutions of phenol. An extension is introduced to account for the chemical reaction between the weak acid phenol and the strong base sodium hydroxide. The prediction results nicely agree with the new experimental data. © 2015 American Institute of Chemical Engineers AIChE J, 61: 2832–2840, 2015     

Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease

The two SARS-CoV-2 proteases, i. e. the main protease (M^pro) and the papain-like protease (PL^pro), which hydrolyze the viral polypeptide chain giving functional non-structural proteins, are essential for viral replication and are medicinal chemistry targets. We report a high-throughput mass spectrometry (MS)-based assay which directly monitors PL^pro catalysis in vitro. The assay was applied to investigate the effect of reported small-molecule PL^pro inhibitors and selected M^pro inhibitors on PL^pro catalysis. The results reveal that some, but not all, PL^pro inhibitor potencies differ substantially from those obtained using fluorescence-based assays. Some substrate-competing M^pro inhibitors, notably PF-07321332 (nirmatrelvir) which is in clinical development, do not inhibit PL^pro. Less selective M^pro inhibitors, e. g. auranofin, inhibit PL^pro, highlighting the potential for dual PL^pro/M^pro inhibition. MS-based PL^pro assays, which are orthogonal to widely employed fluorescence-based assays, are of utility in validating inhibitor potencies, especially for inhibitors operating by non-covalent mechanisms.     

Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides

Hemopoiesis is disturbed in bone marrow-involving cancers like leukemia and neuroblastoma. Shedding of gangliosides by tumor cells may contribute to this tumor-induced bone marrow suppression. We studied in vitro the inhibitory effects of murine neuroblastoma cells (Neuro-2a and C1300) and their gangliosides on hemopoiesis using normal murine hemopoietic progenitor colony-forming assays. Transwell cultured neuroblastoma cells showed a dose-dependent inhibition on hemopoiesis, indicating that a soluble factor was responsible for this effect. Furthermore, the supernatant of Neuro-2a cultured cells inhibited hemopoietic proliferation and differentiation. To determine whether the inhibitory effect was indeed due to shed gangliosides and not, for instance, caused by cytokines, the effect of DL-threo-1 -phenyl-2-decanoylamino-3-morpholino-1-propanol (DL-PDMP) on Neuro-2a cells was studied. DL-PDMP is a potent inhibitor of glucosylceramide synthase, resulting in inhibition of the synthesis and shedding of gangliosides. The initially observed inhibitory effect of supernatant of Neuro-2a cells was abrogated by culturing these cells for 3 days in the presence of 10 microM DL-PDMP. Moreover, gangliosides isolated from Neuro-2a cell membranes inhibited hemopoietic growth. To determine whether the described phenomena in vitro are a reflection of bone marrow suppression occurring in vivo, gangliosides isolated from plasma of neuroblastoma patients were tested for their effects on human hemopoietic progenitor colony-forming assays. These human neuroblastoma-derived gangliosides inhibited normal erythropoiesis (colony-forming unit-erythroid/burst-forming unit-erythroid) and myelopoiesis (colony-forming unit-granulocyte/macrophage) to a higher extent compared with gangliosides isolated from control plasma. Altogether these results suggest that gangliosides shed by neuroblastoma cells inhibit hemopoiesis and may contribute to the observed bone marrow depression in neuroblastoma patients.